에 대한 최신 뉴스 Veeva Systems (NYSE:VEEV) 주식

Veeva Systems

Veeva Sys

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

Large Cap

News

Movers

Trading Ideas

AFRM

AZPN

NTNX

PODD

TCOM

VEEV

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 어펌 홀딩스(NASDAQ:AFRM)의 주가는 강력한 4분기 실적과 낙관적인 1분기 가이던스에 따라 36.04% 상승했다. 몇몇 분석가는 주가 전망을 상향 조정했다.

어펌 및 몽고DB는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 25일-8월 31일)

Veeva Systems Inc

Truist Securities analyst Jailendra Singh maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Hold and lowers the price target from $261 to $210.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Veeva Systems, Lowers Price Target to $210

Keybanc analyst Scott Schoenhaus maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and lowers the price target from $285 to $255.

Keybanc Maintains Overweight on Veeva Systems, Lowers Price Target to $255

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$142.00</td>
<td>$132.6K</td>
<td>236</td>
<td>1.1K</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$35.0K</td>
<td>3.7K</td>
<td>750</td>
</tr>
<tr>
<td>SOLV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$70.00</td>
<td>$25.0K</td>
<td>711</td>
<td>608</td>
</tr>
<tr>
<td>GEHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$92.50</td>
<td>$83.4K</td>
<td>14</td>
<td>340</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$210.00</td>
<td>$87.3K</td>
<td>2.5K</td>
<td>284</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$45.00</td>
<td>$28.6K</td>
<td>53.7K</td>
<td>193</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$110.00</td>
<td>$106.5K</td>
<td>210</td>
<td>101</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$220.00</td>
<td>$64.2K</td>
<td>184</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option trade with neutral sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 829 contract(s) at a $142.00 strike. The total cost received by the writing party (or parties) was $132.6K, with a price of $160.0 per contract. There were 236 open contracts at this strike prior to today, and today 1103 contract(s) were bought and sold. 
• For CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on January 17, 2025. This event was a transfer of 250 contract(s) at a $15.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $140.0 per contract. There were 3727 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding SOLV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $250.0 per contract. There were 711 open contracts at this strike prior to today, and today 608 contract(s) were bought and sold. 
• For GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we notice a call option sweep that happens to be bearish, expiring in 254 day(s) on September 19, 2025. This event was a transfer of 139 contract(s) at a $92.50 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $83.4K, with a price of $600.0 per contract. There were 14 open contracts at this strike prior to today, and today 340 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bullish sentiment. It expires in 373 day(s) on January 16, 2026. Parties traded 148 contract(s) at a $210.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $87.3K, with a price of $590.0 per contract. There were 2546 open contracts at this strike prior to today, and today 284 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option trade that happens to be bullish, expiring in 44 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $28.6K, with a price of $286.0 per contract. There were 53788 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 254 day(s) on September 19, 2025. Parties traded 101 contract(s) at a $110.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1055.0 per contract. There were 210 open contracts at this strike prior to today, and today 101 contract(s) were bought and sold. 
• For VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we notice a call option trade that happens to be neutral, expiring in 373 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $64.2K, with a price of $3210.0 per contract. There were 184 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

CAPR

GEHC

SOLV

8 Health Care Stocks Whale Activity In Today's Session

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.57% on an annualized basis producing an average annual return of 22.81%. Currently, Veeva Systems has a market capitalization of $34.44 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $7,821.72 today based on a price of $212.12 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735830010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Veeva Systems 10 Years Ago Would Be Worth This Much Today

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 12.91% on an annualized basis producing an average annual return of 23.94%. Currently, Veeva Systems has a market capitalization of $36.44 billion. 
Buying $100 In VEEV: If an investor had bought $100 of VEEV stock 10 years ago, it would be worth $837.57 today based on a price of $224.43 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734964211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has been analyzed by 26 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">12</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Veeva Systems, presenting an average target of $264.27, a high estimate of $307.00, and a low estimate of $195.00. Observing a 7.81% increase, the current average has risen from the previous average price target of $245.13. 
<img src="https://www.benzinga.com/files/images/story/2024/1734728477_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Veeva Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$195.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$218.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$307.00</td>
<td>$281.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$245.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$272.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$261.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$270.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$235.00</td>
<td>-</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$245.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Andrew DeGasperi</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Outperform</td>
<td>$286.00</td>
<td>-</td>
</tr>
<tr>
<td>Jack Wallace</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$249.00</td>
<td>$233.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veeva Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veeva Systems compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Veeva Systems's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veeva Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VEEV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veeva Systems analyst ratings.</a>
<h2>Discovering Veeva Systems: A Closer Look</h2>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>Veeva Systems: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Veeva Systems's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 13.41%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.57%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Veeva Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.48%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Veeva Systems's ROA excels beyond industry benchmarks, reaching 2.91%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Veeva Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 26 Analyst Ratings Have To Say About Veeva Systems

Stephens &amp; Co. analyst Jeff Garro initiates coverage on Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight rating.

Initiation

Stephens & Co. Initiates Coverage On Veeva Systems with Overweight Rating

Morgan Stanley analyst Craig Hettenbach maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Underweight and raises the price target from $183 to $195.

Morgan Stanley Maintains Underweight on Veeva Systems, Raises Price Target to $195

JP Morgan analyst Anne Samuel maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Neutral and raises the price target from $208 to $218.

JP Morgan Maintains Neutral on Veeva Systems, Raises Price Target to $218

Veeva Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) short percent of float has fallen 16.87% since its last report. The company recently reported that it has 1.97 million shares sold short, which is 1.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Veeva Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734025511_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Veeva Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Veeva Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Veeva Systems's peer group average for short interest as a percentage of float is 6.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(VEEV) - Analyzing Veeva Systems's Short Interest

Citigroup analyst Tyler Radke maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $281 to $307.

Citigroup Maintains Buy on Veeva Systems, Raises Price Target to $307

Mizuho analyst Steven Valiquette maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $275 to $280.

Mizuho Maintains Outperform on Veeva Systems, Raises Price Target to $280

Scotiabank analyst Allan Verkhovski maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Sector Perform and raises the price target from $235 to $240.

Scotiabank Maintains Sector Perform on Veeva Systems, Raises Price Target to $240

The S&amp;P 500 and the Nasdaq 100 are set to log their <a href="https://www.benzinga.com/markets">third consecutive week of gains</a>. 
The Nasdaq 100, in particular, is tracking its strongest weekly performance in a month, underscoring investor enthusiasm for tech stocks and the growing likelihood <a href="https://www.benzinga.com/topic/interest-rates">of lower interest rates.</a>
Meanwhile, the Dow Jones Industrial Average is on course to finish the week in negative territory, highlighting a divergence in performance among major U.S. indices.
Shares of Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) surged 3% on Wednesday, extending their weekly gain to over 9%, marking the stock's best week since late January. The rally followed a U.S. appeals court decision upholding the Jan. 19 deadline for TikTok's parent company, ByteDance, to divest the app over national security and data privacy concerns. TikTok's appeal was rejected, leaving the U.S. Supreme Court as its final recourse.
The consumer discretionary sector emerged as Friday's best performer, fueled by further gains in Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In macro news, November nonfarm payrolls rose by 227,000, beating consensus estimates, while the unemployment rate edged higher to 4.2%, as expected. Wage growth slightly outpaced forecasts, signaling <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42363278/us-economy-adds-227000-jobs-in-november-wage-growth-accelerates">resilience in the labor market.</a>
Meanwhile, the University of Michigan&#8217;s consumer sentiment index climbed to its most optimistic level since April but hinted at growing concerns about near-term inflation, reflecting a mixed <a href="https://www.benzinga.com/news/econ-s/24/12/42366245/consumer-sentiment-hits-7-month-high-but-inflation-fears-divide-democrats-republicans">sentiment among U.S. consumers.</a>
The U.S. dollar gained traction, with the dollar index rising 0.3% despite market participants raised expectations of an interest rate cut at the Federal Reserve's Dec. 18 meeting. Treasury yields eased, reflecting bolstered expectations of policy easing.
Chicago Fed President Austan Goolsbee hinted at upcoming Federal Reserve meetings being "close calls" between cutting rates or holding steady, keeping traders on edge.
Commodities saw muted moves on Friday. Gold prices were flat, consolidating near recent levels, while crude oil slid 1.2%. 
The cryptocurrency market lit up on Friday, driven by significant gains in major digital assets. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), for example, surged over 4%, breaching the $101,500 level at last check Friday. 
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) rallied 6%, reflecting robust investor appetite across the sector.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,600.05</td>
<td>0.8%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,405.74</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,089.46</td>
<td>0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,674.60</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120224&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.3% up to $608.20.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $447.87.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.9% to $526.50.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.4% to $239.03.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 1.3%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.3%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) skyrocketed by about 18% in reaction to company&#8217;s quarterly results. </li>
<li>Other stocks reacting to earnings reports included Hewlett Packard Enterprise Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>), up 10%, DocuSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>), up 27%, Ulta Beauty Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), up 10%, Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) up 8% and Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>), down over 5%. </li>
<li>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) fell 4.4%, continuing to slid after Brian Thomson&#8217;s death and marking the Dow&#8217;s worst performer on Friday. </li>
</ul>
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling">TikTok Loses Court Appeal Against Ban, Meta, Reddit Stocks Hit All-Time High</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Macro Economic Events

Mid Cap

Sector ETFs

Social Media

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

$ETH

AMZN

SPDR Dow Jones Industrial Average ETF Trust

DOCU

LULU

TSLA

ULTA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Rise; Meta Rallies As Court Upholds Tiktok Ban; Bitcoin Roars Above $101,000: What's Driving Markets Friday?

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $260 to $275.

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $275

Evercore ISI Group analyst Kirk Materne maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a In-Line and raises the price target from $220 to $245.

Evercore ISI Group Maintains In-Line on Veeva Systems, Raises Price Target to $245

B of A Securities analyst Brad Sills maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Neutral and raises the price target from $280 to $290.

B of A Securities Maintains Neutral on Veeva Systems, Raises Price Target to $290

U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Friday.
Shares of Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) rose sharply during Friday&#8217;s session after the company reported better-than-expected third-quarter financial results and <a href="https://www.benzinga.com/24/12/42368761/whats-going-on-with-ulta-beauty-stock-friday">raised its FY24 outlook</a>.
Ulta Beauty reported quarterly earnings of $5.14 per share, which beat the analyst consensus estimate of $4.54. Quarterly revenue came in at $2.53 billion, which beat the analyst consensus estimate of $2.5 billion and is an increase over sales of $2.49 billion from the same period last year.
Also, Telsey Advisory Group maintained an Outperform rating on the stock and raised its price target from $450 to $500.
Ulta Beauty shares jumped 10.4% to $433.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares jumped 52.5% to $15.39.</li>
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) jumped 41.6% to $21.89 after the company reported better-than-expected third-quarter financial results and issued FY25 guidance above estimates. Also, Piper Sandler and Baird raised their respective price targets on the stock.</li>
<li>Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) gained 33.3% to $71.54 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates. Also, Keybanc maintained an Overweight rating on the stock and raised its price target from $57 to $75.</li>
<li>Nano-X Imaging Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) surged 29.5% to $8.08. Cantor Fitzgerald analyst Ross Osborn maintained Nano X Imaging with an Overweight and raised the price target from $11 to $12.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) gained 28.6% to $4.8465.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) surged 25.9% to $4.0050.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) gained 25.2% to $104.79 after the company reported better-than-expected third-quarter financial results and issued FY25 revenue guidance above estimates.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) climbed 21.5% to $11.58.</li>
<li>Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) gained 20.8% to $2.72 after Rosenblatt maintained a Buy rating on the stock and raised its price target from $3 to $4.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 19.8% to $7.90.</li>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) rose 18.2% to $407.50 following upbeat quarterly earnings.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) gained 15% to $31.77 after the company provided operational updates for November 2024. The company produced 94 BTC for a total of 9,122 on its balance sheet.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) surged 14.7% to $7.94.</li>
<li>Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) rose 10.8% to $24.00 after the company reported better-than-expected quarterly financial results.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) gained 10.8% to $24.96.</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) gained 10.3% to $255.60 after the company reported a year-over-year increase in third-quarter financial results. Also, Piper Sandler and Needham raised their respective price targets on the stock.</li>
<li>Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) jumped 9% to $46.91 following third-quarter results.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) gained 8.7% to $53.62.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 7.7% to $408.34 after Macquarie maintained an Outperform rating on the stock and raised its price target from $270 to $450.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42364367/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

Earnings

Eurozone

Markets

ASAN

ASTS

NNOX

QBTS

RBRK

RGTI

RXRX

SERV

VSCO

Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday

RBC Capital analyst Rishi Jaluria maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $275 to $285.

RBC Capital Maintains Outperform on Veeva Systems, Raises Price Target to $285

Stifel analyst David Grossman maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $240 to $272.

Stifel Maintains Buy on Veeva Systems, Raises Price Target to $272

IHF: Healthcare Dashboard For December

Stephens analyst Jeff Garro initiated coverage of Veeva (VEEV) with an Overweight rating and $280 price target The company's sales growth stabilizi...

Veeva initiated with an Overweight at Stephens

Hartford MidCap Fund Q3 2024 Commentary

Wells Fargo added Veeva (VEEV) to the firm's Q1 "Tactical Ideas List." The firm believes Veeva is poised to re-rate higher on improving line of sig...

Veeva added to Q1 'Tactical Ideas List' at Wells Fargo

Evercore's AI enablers, adopters and adapters: CRM, MU, CI, EQT and more

In a report released today, Craig Hettenbach from Morgan Stanley maintained a Sell rating on Veeva Systems (VEEV – Research Report), with a price t...

Veeva Systems (VEEV) Gets a Sell from Morgan Stanley

Veeva: My Software Pick For 2025

KeyBanc lowered the firm's price target on Veeva (VEEV) to $255 from $285 and keeps an Overweight rating on the shares. The firm notes healthcare t...

Veeva price target lowered to $255 from $285 at KeyBanc

Veeva's Vault Is Safe-But What About Its CRM Offering

Wells Fargo analyst Stan Berenshteyn believes Veeva (VEEV) appears poised to outperform the market with an attractive risk/reward setup. Strategic ...

Veeva named top pick for 2025 at Wells Fargo

AIEQ

CFLT

CNMD

COLL

CYBR

DDOG

DKNG

DOCS

ESTC

FICO

GOOGL

GTLB

HRMY

HSRT

HUBS

LNTH

MPWR

NCLH

NWSA

PAYC

SNOW

TEAM

TMUS

TRGP

TWLO

Press Releases

Boehringer Ingelheim Commits to Veeva Vault CRM

Veeva to Release Fiscal 2025 Third Quarter Results on December 5, 2024

Veeva Announces New Digital Hazard Analysis and Critical Control Point (HACCP) Solution

Veeva Announces AI in Vault CRM

Report Reveals 70% of Medtechs Use Manual Processes for Managing Content and Claims

Veeva Announces Fiscal 2025 Third Quarter Results

Veeva to Present at Upcoming Investor Conference

Veeva Delivers Vault CRM Suite with Vault CRM Campaign Manager

A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OneMedNet

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Waystar Holding

Truist Securities

Keybanc

Morgan Stanley

JP Morgan

Citigroup

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)의 주가는 강력한 4분기 실적과 낙관적인 <a href="https://www.benzinga.com//node/40613433" target="_blank" rel="noreferrer noopener">1분기 가이던스</a>에 따라 36.04% 상승했다. 몇몇 분석가는 <a href="https://www.benzinga.com//node/40630056" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
2. 뉴타닉스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>)는 회사가 4분기 재무 결과를 보고하고 1분기 및 2025 회계연도 <a href="https://www.benzinga.com//node/40614905" target="_blank" rel="noreferrer noopener">매출 가이던스를 예상치</a>보다 높게 발표한 후 18.80% 상승했다. 많은 분석가들이 <a href="https://www.benzinga.com//node/40626089" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
3. 몽고DB(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)는 예상보다 나은 2분기 재무 결과와 강력한 지침을 발표하여 지난주 주가가 16.32% 상승했다. 몇몇 분석가들이 <a href="https://www.benzinga.com/quote/MDB/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
4. 베스트 바이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)가 2분기 실적을 보고하고 <a href="https://www.benzinga.com//node/40624075" target="_blank" rel="noreferrer noopener">2025 회계연도 실적 가이던스를 상향 조정</a>한 후 주가는 13.54% 상승했다. 몇몇 분석가들은 <a href="https://www.benzinga.com//node/40651188" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주식에 대한 전망을 높였다</a>.
5. GE 베르노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)의 주식은 투자 은행 윌리엄 블레어(William Blair)가 주식을 <a href="https://www.benzinga.com/quote/GEV/analyst-ratings" target="_blank" rel="noreferrer noopener">아웃퍼폼 등급으로 커버리지를 개시</a>한 후 11.62% 상승했다.
6. 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40564652" target="_blank" rel="noreferrer noopener">분기 실적을 발표</a>한 후 11.42% 상승했다.
7. 쿠퍼 컴퍼니스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>)의 주식은 3분기 실적을 발표하고 예상치를 상회하는 <a href="https://www.benzinga.com//node/40611992" target="_blank" rel="noreferrer noopener">4분기 및 2025 회계연도 가이던스를 발표</a>한 후 11.30% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/COO/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
8. 인슐렛 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)의 주식은 최근 자사의 패치형 웨어러블 인슐린 펌프인 옴니팟(Omnipod)이 <a href="https://www.benzinga.com//node/40562757" target="_blank" rel="noreferrer noopener">미국에서 제2형 당뇨병 환자</a>에게 사용하도록 지정되었다고 발표한 후 주가는 9.94% 상승했다.
9. 비바 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>)의 주식은 회사가 재무 실적을 발표하고 3분기 및 2025 회계연도 조정 <a href="https://www.benzinga.com//node/40611557" target="_blank" rel="noreferrer noopener">EPS 가이던스를 예상치 이상으로 발표</a>한 후 8.44% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/veev/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
10. 아스펜 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>)의 주식은 8.12% 상승했다.
다음 읽기:
<a href="https://kr.benzinga.com/news/usa/stocks/%eb%8b%ac%eb%9f%ac-%ec%a0%9c%eb%84%88%eb%9f%b4-%eb%b0%8f-%ed%85%8c%eb%ac%b4%ec%9d%98-%eb%aa%a8%ed%9a%8c%ec%82%ac-pdd%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc/" target="_blank" rel="noopener">달러 제너럴 및 PDD는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 25일-8월 31일)</a>
Affirm 제공
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Veeva Systems

뉴스

에 대한 최신 뉴스 Veeva Systems (NYSE:VEEV) 주식

화요일, 9월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌